Trials / Completed
CompletedNCT00159081
One Year Drug Treatment in First-Episode Schizophrenia
One Year Maintenance Treatment With Low Dose Haloperidol vs. Risperidone in First-Episode Schizophrenia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- Heinrich-Heine University, Duesseldorf · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.
Detailed description
The objective of this multi-center study is to optimize the long-term treatment of patients with first episode schizophrenia. This investigation should contribute to the issue of effective relapse prevention in first-episode patients. 1-year maintenance neuroleptic treatment is done with low dose haloperidol or risperidone (target dose 2-4 mg/die).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Haloperidol, Risperidone (drug) | targeted dose of 2-4 mg/day over 1 year |
Timeline
- Start date
- 2000-11-01
- Primary completion
- 2005-06-01
- Completion
- 2005-06-01
- First posted
- 2005-09-12
- Last updated
- 2008-02-07
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00159081. Inclusion in this directory is not an endorsement.